{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T09:51:02Z","timestamp":1774259462364,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd009355","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,11,14]],"date-time":"2012-11-14T00:00:00Z","timestamp":1352851200000}}],"reference-count":40,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009355.pub2","type":"journal-article","created":{"date-parts":[[2012,11,8]],"date-time":"2012-11-08T19:37:16Z","timestamp":1352403436000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL)"],"prefix":"10.1002","volume":"2012","author":[{"given":"Nicole","family":"Bergner","sequence":"first","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ina","family":"Monsef","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Illerhaus","sequence":"additional","affiliation":[{"name":"University Hospital of Freiburg; Department I of Internal Medicine; Freiburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,11,14]]},"reference":[{"key":"10.1002\/14651858.CD009355.pub2-BIB0001|cit1","first-page":"158","article-title":"Randomized phase II trial on primary chemotherapy with high-dose methotrexate (MTX) alone or associated with high-dose cytarabine (ARA-C) for patients with primary CNS lymphoma (PCNSL): The International Extranodal Lymphoma Study Group (IELSG) #20 Trial","volume":"93","author":"Ferreri","year":"2008","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD009355.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","article-title":"High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial","volume":"374","author":"Ferreri","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD009355.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1182\/blood.V112.11.580.580","article-title":"Randomized phase II trial on primary chemotherapy with high-dose methotrexate alone or associated with high-dose cytarabine for patients with primary CNS lymphoma (IELSG #20 Trial): tolerability, activity and event-free survival analysis","volume":"112","author":"Ferreri","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD009355.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1200\/jco.2009.27.15_suppl.8545","article-title":"Randomized phase II trial on primary chemotherapy with high-dose methotrexate (HD-MTX) alone or associated with high-dose cytarabine (HD-araC) for patients with primary CNS lymphoma (I.E.L.S.G. # 20 Trial): tolerability, activity, and survival analyses [abstract no. 8545]","volume":"27","author":"Ferreri","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD009355.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.nurt.2009.04.013","article-title":"Biology and treatment of primary central nervous system lymphoma","volume":"6","author":"Algazi","year":"2009","journal-title":"Neurotherapeutics"},{"key":"10.1002\/14651858.CD009355.pub2-BIB0006|cit6","first-page":"654","article-title":"Prim\u00e4re ZNS-lymphome (PCNSL)","volume-title":"Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie","author":"AWMF-Guideline","year":"2008"},{"issue":"2","key":"10.1002\/14651858.CD009355.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3171\/jns.2000.92.2.0261","article-title":"Primary intracerebral malignant lymphoma: report of 248 cases","volume":"92","author":"Bataille","year":"2000","journal-title":"Journal of Neurosurgery"},{"issue":"2","key":"10.1002\/14651858.CD009355.pub2-BIB0008|cit8","first-page":"711","article-title":"High-dose methotrexate for intraocular lymphoma","volume":"9","author":"Batchelor","year":"2003","journal-title":"Clinical Cancer Research"},{"issue":"8","key":"10.1002\/14651858.CD009355.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1200\/JCO.2005.04.8819","article-title":"Primary CNS lymphoma","volume":"24","author":"Batchelor","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD009355.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11060-009-0090-3","article-title":"Monotherapy with methotrexate for primary central nervous lymphoma has single agent activity in the absence of radiotherapy: a single institution cohort","volume":"98","author":"Cobert","year":"2010","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1002\/14651858.CD009355.pub2-BIB0011|cit11","article-title":"Chapter 9: Analysing data and undertaking meta-analyses","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Deeks","year":"2011"},{"issue":"10","key":"10.1002\/14651858.CD009355.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1212\/WNL.58.10.1513","article-title":"A multicenter study of treatment of primary CNS lymphoma","volume":"58","author":"Ferreri","year":"2002","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD009355.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1200\/JCO.2003.01.135","article-title":"Summary statement on primary central nervous system lymphomas from the eighth international conference on malignant lymphoma, Lugano, Switzerland, June 12 to 15, 2002","volume":"21","author":"Ferreri","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD009355.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","article-title":"Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience","volume":"21","author":"Ferreri","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD009355.pub2-BIB0015|cit15","doi-asserted-by":"crossref","unstructured":"Ferreri AJ Reni M Foppoli M Martelli M Pangalis GA Frezzato M High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial Lancet 2009 1512 20","DOI":"10.1016\/S0140-6736(09)61416-1"},{"issue":"1","key":"10.1002\/14651858.CD009355.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijrobp.2010.01.066","article-title":"Consolidation radiotherapy in primary central nervous system lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy","volume":"80","author":"Ferreri","year":"2011","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"9","key":"10.1002\/14651858.CD009355.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1093\/annonc\/mdq712","article-title":"Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly","volume":"22","author":"Fritsch","year":"2011","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD009355.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1001\/archneurol.2010.3","article-title":"Primary central nervous system lymphoma","volume":"67","author":"Gerstner","year":"2010","journal-title":"Archives of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD009355.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1586\/14737175.6.5.635","article-title":"Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma","volume":"6","author":"Green","year":"2006","journal-title":"Expert Review of Neurotherapeutics"},{"issue":"3","key":"10.1002\/14651858.CD009355.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1006210703827","article-title":"Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients","volume":"43","author":"Guha-Thakurta","year":"1999","journal-title":"Journal of Neuro-oncology"},{"issue":"6","key":"10.1002\/14651858.CD009355.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/ana.20495","article-title":"NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report","volume":"57","author":"Herrlinger","year":"2005","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD009355.pub2-BIB0022|cit22","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Higgins","year":"2011"},{"key":"10.1002\/14651858.CD009355.pub2-BIB0023|cit23","article-title":"Chapter 7: Selecting studies and collecting data","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Higgins","year":"2011"},{"key":"10.1002\/14651858.CD009355.pub2-BIB0024|cit24","article-title":"Chapter 16: Special topics in statistics","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Higgins","year":"2011"},{"issue":"24","key":"10.1002\/14651858.CD009355.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1200\/JCO.2006.06.2117","article-title":"High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma","volume":"24","author":"Illerhaus","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD009355.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/annonc\/mdn628","article-title":"High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study","volume":"20","author":"Illerhaus","year":"2009","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD009355.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/annonc\/mdi075","article-title":"High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma","volume":"16","author":"Jahnke","year":"2005","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD009355.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.10643","article-title":"Decreasing incidence rates of primary central nervous system lymphoma","volume":"95","author":"Kadan-Lottick","year":"2002","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD009355.pub2-BIB0029|cit29","article-title":"Chapter 6: Searching for studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Lefebvre","year":"2011"},{"key":"10.1002\/14651858.CD009355.pub2-BIB0030|cit30","volume-title":"Guidelines on the diagnosis and management of adult patients with primary cns lymphoma (PCNSL) and primary intra-ocular lymphoma (PIOL)","author":"Marcus","year":"2007"},{"issue":"10","key":"10.1002\/14651858.CD009355.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement","volume":"62","author":"Moher","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD009355.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11060-010-0269-7","article-title":"Survival among patients with primary central nervous system lymphoma, 1973\u20132004","volume":"101","author":"Norden","year":"2010","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1002\/14651858.CD009355.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"TPS144","DOI":"10.1200\/jco.2010.28.15_suppl.tps144","article-title":"Multicenter randomized phase II trial of methotrexate (MTX) and temozolomide (TMZ) versus MTX, procarbazine (PCB), vincristine (VINC), and cytarabine (Ara-C) for primary CNS lymphoma (PCNSL) in elderly patients","volume":"28 Suppl 15","author":"Omuro","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"24","key":"10.1002\/14651858.CD009355.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD009355.pub2-BIB0035|cit35","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (Revman) 2011"},{"issue":"s1","key":"10.1002\/14651858.CD009355.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/10428190802311441","article-title":"Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment","volume":"49","author":"Rubenstein","year":"2008","journal-title":"Leukemia & Lymphoma"},{"key":"10.1002\/14651858.CD009355.pub2-BIB0037|cit37","article-title":"Chapter 10: Addressing reporting biases","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Sterne","year":"2011"},{"key":"10.1002\/14651858.CD009355.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"5","key":"10.1002\/14651858.CD009355.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/cncr.10357","article-title":"Primary central nervous system lymphomas: incidence and survival in the Southern and Eastern Netherlands","volume":"94","author":"Sanden","year":"2002","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD009355.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/A:1023760824739","article-title":"Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy","volume":"63","author":"Watanabe","year":"2003","journal-title":"Journal of Neuro-oncology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD009355.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T08:52:40Z","timestamp":1774255960000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009355.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Haematological Malignancies Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2012,11,14]]},"references-count":40,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2012,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009355.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,14]]}}}